Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2022 16:00

RNS Number : 9118D
ReNeuron Group plc
07 March 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BF5G6K95

Issuer Name

RENEURON GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.734800

3.035000

3.769800

2151158

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BF5G6K95

419300

0.734800

Sub Total 8.A

419300

0.734800%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

1731858

3.035000

Sub Total 8.B1

1731858

3.035000%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASDXESPAEFA
Date   Source Headline
15th Jul 20107:00 amRNSNotification of Investor Evening
12th Jul 20107:00 amRNSResult of pre-clinical studies
29th Jun 20107:00 amRNSPreliminary Results
17th Jun 20107:00 amRNSPreliminary Results Notification
13th May 20102:38 pmRNSBlock listing application
29th Apr 20107:00 amRNSNew positive data to be presented at US conference
1st Apr 20109:58 amRNSHolding in Company
31st Mar 20104:35 pmRNSHolding(s) in Company
22nd Mar 201010:44 amRNSReNeuron cited as UK regenerative medicine leader
18th Mar 20107:00 amRNSReNeuron signs further manufacturing contracts
15th Mar 20102:44 pmRNSSecond Closing of the Placing
12th Mar 201012:18 pmRNSResult of General Meeting
3rd Mar 20107:00 amRNSReNeuron presents pre-clinical efficacy data
22nd Feb 20107:00 amRNSReNeuron Announces Fundraising
18th Feb 20107:00 amRNSRetinal Stem Cell Research Grant
10th Feb 20107:00 amRNSFinal Approval Received To Commence Stroke Trial
8th Feb 201012:55 pmRNSIssue of Ordinary Shares
1st Feb 20107:00 amRNSClinical Advisory Board appointments
28th Jan 20107:00 amRNSRegulatory update
27th Jan 201011:42 amRNSReNeuron welcomes "Life Sciences 2010" report
1st Dec 20097:00 amRNSIssue of Ordinary Shares
27th Nov 20097:00 amRNSTwo grants awarded by regenerative funding program
26th Nov 20097:02 amRNS?5 million equity funding facility secured
26th Nov 20097:00 amRNSHalf Yearly Report
23rd Nov 20097:00 amRNSNotice of Results
16th Nov 20097:00 amRNSPositive data presented at leading US conference
22nd Oct 20091:49 pmRNSReNeuron to present at Royal Society of Medicine
2nd Oct 20097:00 amRNSPublication of new research using ReNcell
17th Sep 200910:47 amRNSResult of AGM
17th Sep 20097:00 amRNSAGM Statement
14th Sep 20097:02 amRNSTrading Platform
14th Sep 20097:00 amRNSChange of Adviser
10th Sep 20097:00 amRNSAngel and Reneuron announce contract
10th Sep 20097:00 amRNSRe Agreement
9th Sep 20095:00 pmRNSHolding(s) in Company
12th Aug 20097:00 amRNSDirector/PDMR Shareholding
11th Aug 20097:00 amRNSPublication of papers in peer-reviewed journals
10th Aug 20099:28 amRNSPublication of pre-clinical data
31st Jul 200911:21 amRNS2008/09 Annual Report and Accounts
30th Jul 200910:05 amRNSRegulatory Update
14th Jul 20093:48 pmRNSLaunch of "Life Sciences Blueprint"
8th Jul 20099:33 amRNSPublication of data on lead CTX stem cell line
30th Jun 20097:00 amRNSFinal Results
29th Jun 20093:44 pmRNSHolding(s) in Company
24th Jun 200910:30 amRNSHolding(s) in Company
19th Jun 200912:17 pmRNSNotice of Results
12th Jun 20092:56 pmRNSHolding(s) in Company
9th Jun 20097:00 amRNSStem cells manufacturing contract signed
21st May 20098:43 amRNSHolding(s) in Company
19th May 20091:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.